Annals of Ibadan postgraduate medicine · 2026
CARDIOVASCULAR COMPLICATIONS OF CHEMOTHERAPY IN BREAST CANCER: A SCOPING REVIEW.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orimolade O A, Ogah O S, Ajagbe O A, Adebayo D A, Ayandipo O O, Adebiyi A A, Ogundiran T O
Аннотация
BACKGROUND: Chemotherapy remains a cornerstone in breast cancer management but is associated with significant cardiovascular toxicity, which may adversely affect long-term outcomes. Anthracyclines are particularly implicated due to their dose-dependent cardiotoxic effects.
OBJECTIVE: To synthesize current evidence on chemotherapy-induced cardiotoxicity in breast cancer, with emphasis on anthracycline-related cardiac dysfunction, including epidemiology, mechanisms, risk factors, detection, and prevention.
METHODS: A scoping review of peer-reviewed literature was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Studies evaluating cardiovascular complications of chemotherapy in breast cancer were included.
RESULTS: Cardiotoxicity risk is associated with cumulative anthracycline dose, concurrent use of cardiotoxic agents such as trastuzumab, and pre-existing cardiovascular disease. Mechanisms include oxidative stress, mitochondrial dysfunction, and topoisomerase II inhibition. Early detection using speckletracking echocardiography and biomarkers such as troponins and natriuretic peptides allows identification of subclinical myocardial injury. Preventive strategies-including dose modification, liposomal anthracyclines, and cardioprotective agents such as dexrazoxane, beta-blockers, and ACE inhibitors-demonstrate benefit.5/13/2026.
CONCLUSION: Chemotherapy-induced cardiotoxicity remains a major clinical challenge. Early detection, risk stratification, and integrated cardio-oncology care are essential to improving outcomes in breast cancer patients.
OBJECTIVE: To synthesize current evidence on chemotherapy-induced cardiotoxicity in breast cancer, with emphasis on anthracycline-related cardiac dysfunction, including epidemiology, mechanisms, risk factors, detection, and prevention.
METHODS: A scoping review of peer-reviewed literature was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Studies evaluating cardiovascular complications of chemotherapy in breast cancer were included.
RESULTS: Cardiotoxicity risk is associated with cumulative anthracycline dose, concurrent use of cardiotoxic agents such as trastuzumab, and pre-existing cardiovascular disease. Mechanisms include oxidative stress, mitochondrial dysfunction, and topoisomerase II inhibition. Early detection using speckletracking echocardiography and biomarkers such as troponins and natriuretic peptides allows identification of subclinical myocardial injury. Preventive strategies-including dose modification, liposomal anthracyclines, and cardioprotective agents such as dexrazoxane, beta-blockers, and ACE inhibitors-demonstrate benefit.5/13/2026.
CONCLUSION: Chemotherapy-induced cardiotoxicity remains a major clinical challenge. Early detection, risk stratification, and integrated cardio-oncology care are essential to improving outcomes in breast cancer patients.